Hépatotoxicité des antituberculeux de première ligne (notice n° 666371)
[ vue normale ]
| 000 -LEADER | |
|---|---|
| fixed length control field | 02776cam a2200349 4500500 |
| 005 - DATE AND TIME OF LATEST TRANSACTION | |
| control field | 20250121194216.0 |
| 041 ## - LANGUAGE CODE | |
| Language code of text/sound track or separate title | fre |
| 042 ## - AUTHENTICATION CODE | |
| Authentication code | dc |
| 100 10 - MAIN ENTRY--PERSONAL NAME | |
| Personal name | Kpossou, Aboudou Raïmi |
| Relator term | author |
| 245 00 - TITLE STATEMENT | |
| Title | Hépatotoxicité des antituberculeux de première ligne |
| 260 ## - PUBLICATION, DISTRIBUTION, ETC. | |
| Date of publication, distribution, etc. | 2024.<br/> |
| 500 ## - GENERAL NOTE | |
| General note | 38 |
| 520 ## - SUMMARY, ETC. | |
| Summary, etc. | Tuberculosis is a worldwide public health problem, particularly in developing countries. Anti-tuberculosis treatment, which combines several drugs over several months, is potentially hepatotoxic. Hepatotoxicity spectrum of anti-tuberculosis drugs ranges from a simple transient disturbance of the liver tests to fulminant hepatitis, requiring immediate discontinuation of anti-tuberculosis drugs. The anti-tuberculosis drugs responsible are isoniazid, pyrazinamide and rifampicin. The best way to prevent hepatitis is to identify certain risk factors before starting treatment, and to ensure adequate monitoring. Anti-tuberculosis treatment, discontinued in the event of severe hepatotoxicity, may be reinstated once liver tests have returned to normal value. |
| 520 ## - SUMMARY, ETC. | |
| Summary, etc. | La tuberculose représente un problème de santé publique mondial et plus particulièrement dans les pays en voie de développement. Le traitement antituberculeux qui associe plusieurs médicaments durant plusieurs mois est potentiellement hépatotoxique. Le spectre de cette hépatotoxicité peut aller d’une simple perturbation transitoire du bilan hépatique jusqu’à l’hépatite fulminante imposant l’arrêt immédiat des antibacillaires. Les antituberculeux responsables sont l’isoniazide, la pyrazinamide et la rifampicine. La meilleure prévention reste la mise en évidence de certains facteurs de risque avant l’instauration du traitement et une surveillance adéquate. Le traitement antituberculeux, arrêté en cas d’hépatotoxicité sévère, peut habituellement être repris après normalisation des tests fonctionnels hépatiques. |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | tuberculose |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | traitement antituberculeux |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | hépatotoxicité |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | cytolyse hépatique |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | hepatic cytolysis |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | hepatotoxicity |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | tuberculosis |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | antituberculosis treatment |
| 700 10 - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Efole, Jean René Ngele |
| Relator term | author |
| 700 10 - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Cadranel, Jean-François |
| Relator term | author |
| 700 10 - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Wachinou, Ablo Prudence |
| Relator term | author |
| 700 10 - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Zougmoré, Honoré T. |
| Relator term | author |
| 700 10 - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Nouel, Olivier |
| Relator term | author |
| 700 10 - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Séhonou, Jean |
| Relator term | author |
| 700 10 - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Mutumwinka, Nina Marcelle |
| Relator term | author |
| 786 0# - DATA SOURCE ENTRY | |
| Note | Hépato-Gastro & Oncologie Digestive | 31 | 6 | 2024-06-02 | p. 596-600 | 2115-3310 |
| 856 41 - ELECTRONIC LOCATION AND ACCESS | |
| Uniform Resource Identifier | <a href="https://shs.cairn.info/revue-hepato-gastro-et-oncologie-digestive-2024-6-page-596?lang=fr&redirect-ssocas=7080">https://shs.cairn.info/revue-hepato-gastro-et-oncologie-digestive-2024-6-page-596?lang=fr&redirect-ssocas=7080</a> |
Pas d'exemplaire disponible.
Réseaux sociaux